Premium
Studies and characterization of a murine neuroblastoma model
Author(s) -
Keogh Brian,
Chu T. Ming,
Williams Phyllis,
Moore Robert H.,
Murphy Gerald P.
Publication year - 1976
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930080602
Subject(s) - vincristine , cyclophosphamide , neuroblastoma , medicine , chemotherapy , autopsy , placebo , pathology , biology , alternative medicine , genetics , cell culture
Clinical chemotherapy in the treatment of neuroblastoma is undergoing further evaluation. Chemotherapeutic agents, cyclophosphamide, vincristine, and hexamethylmelamine, were investigated in a murine neuroblastoma model that, in part, histologically and morphologically resembles the human tumor. The tumor was inoculated subcutaneously (SC), intramuscularly (IM), intraperitoneally (IP), intrarenally (IR). Growth of tumor was observed at all sites, as well as the appearance of metastases. Maximal survival of 32 ± 1 days was seen (SC) and the minimum was 15 ± 1 days (IR) (p < 0.05). Corresponding survival rate for IM was 26 ± 1 days and IP 21 ± 1 days. For this reason SC was selected for drug testing. Cyclophosphamide 100 mg/kg/week showed the most favorable results, as determined by autopsy status with fewer tumors and a greater tumor weight decrease over time. This agent also showed a significantly longer survival in comparison to all other drugs (p < 0.0001). The results with vincristine and hexamethylmelamine in the dose ranges employed differed little from the placebo, except for the finding of a slight decrease in body weight at autopsy.